373 related articles for article (PubMed ID: 9519948)
1. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.
Paggiaro PL; Dahle R; Bakran I; Frith L; Hollingworth K; Efthimiou J
Lancet; 1998 Mar; 351(9105):773-80. PubMed ID: 9519948
[TBL] [Abstract][Full Text] [Related]
2. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
Burge PS; Calverley PM; Jones PW; Spencer S; Anderson JA; Maslen TK
BMJ; 2000 May; 320(7245):1297-303. PubMed ID: 10807619
[TBL] [Abstract][Full Text] [Related]
3. Controlled short-term trial of fluticasone propionate in ventilator-dependent patients with COPD.
Nava S; Compagnoni ML
Chest; 2000 Oct; 118(4):990-9. PubMed ID: 11035668
[TBL] [Abstract][Full Text] [Related]
4. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma.
Peden DB; Berger WE; Noonan MJ; Thomas MR; Hendricks VL; Hamedani AG; Mahajan P; House KW
J Allergy Clin Immunol; 1998 Jul; 102(1):32-8. PubMed ID: 9679845
[TBL] [Abstract][Full Text] [Related]
5. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations.
Jones PW; Willits LR; Burge PS; Calverley PM;
Eur Respir J; 2003 Jan; 21(1):68-73. PubMed ID: 12570111
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study.
du Bois RM; Greenhalgh PM; Southcott AM; Johnson NM; Harris TA
Eur Respir J; 1999 Jun; 13(6):1345-50. PubMed ID: 10445610
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.
Vestbo J; Sørensen T; Lange P; Brix A; Torre P; Viskum K
Lancet; 1999 May; 353(9167):1819-23. PubMed ID: 10359405
[TBL] [Abstract][Full Text] [Related]
9. Controlled trial of inhaled fluticasone propionate in moderate to severe COPD.
Thompson WH; Carvalho P; Souza JP; Charan NB
Lung; 2002; 180(4):191-201. PubMed ID: 12391509
[TBL] [Abstract][Full Text] [Related]
10. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study.
Hattotuwa KL; Gizycki MJ; Ansari TW; Jeffery PK; Barnes NC
Am J Respir Crit Care Med; 2002 Jun; 165(12):1592-6. PubMed ID: 12070058
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
[TBL] [Abstract][Full Text] [Related]
12. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis.
Balfour-Lynn IM; Klein NJ; Dinwiddie R
Arch Dis Child; 1997 Aug; 77(2):124-30. PubMed ID: 9301350
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma.
ZuWallack R; Adelglass J; Clifford DP; Duke SP; Wire PD; Faris M; Harding SM
Chest; 2000 Aug; 118(2):303-12. PubMed ID: 10936117
[TBL] [Abstract][Full Text] [Related]
14. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma.
Nelson HS; Busse WW; deBoisblanc BP; Berger WE; Noonan MJ; Webb DR; Wolford JP; Mahajan PS; Hamedani AG; Shah T; Harding SM
J Allergy Clin Immunol; 1999 Feb; 103(2 Pt 1):267-75. PubMed ID: 9949318
[TBL] [Abstract][Full Text] [Related]
15. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
16. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
[TBL] [Abstract][Full Text] [Related]
17. A placebo controlled trial of fluticasone propionate in asthmatic children.
MacKenzie CA; Weinberg EG; Tabachnik E; Taylor M; Havnen J; Crescenzi K
Eur J Pediatr; 1993 Oct; 152(10):856-60. PubMed ID: 8223792
[TBL] [Abstract][Full Text] [Related]
18. Fluticasone propionate in asthma: a long term dose comparison study.
Verona E; Petrov D; Cserhati E; Hofman J; Geppe N; Medley H; Hughes S
Arch Dis Child; 2003 Jun; 88(6):503-9. PubMed ID: 12765916
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study.
Wolfe JD; Selner JC; Mendelson LM; Hampel F; Schaberg A
Clin Ther; 1996; 18(4):635-46. PubMed ID: 8879892
[TBL] [Abstract][Full Text] [Related]
20. Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids.
Lumry WR; Conway MM; LaForce CF; Pearlman DS; Scott CA; Herje NE; Wu WW; Crim C
Ann Allergy Asthma Immunol; 2006 Jan; 96(1):51-9. PubMed ID: 16440533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
